Use: The detection of anti-RNAP III antibodies is useful in the diagnosis of SSc and for the identification of patients at risk for developing progressive skin thickening and renal crisis. The prevalence of IgG RNAP III antibodies is from 3 - 58% in SSc patients.

Methodology: Enzyme immunoassay (EIA)